Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
McKesson
Chinese Patent Office
Merck
US Department of Justice
Daiichi Sankyo
Dow
Colorcon

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021842

« Back to Dashboard

NDA 021842 describes ACTOPLUS MET, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from three suppliers. There are thirteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ACTOPLUS MET profile page.

The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for 021842
Tradename:ACTOPLUS MET
Applicant:Takeda Pharms Usa
Ingredient:metformin hydrochloride; pioglitazone hydrochloride
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021842
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA 0093-5049 E 0093-5049-06
ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA 0093-5049 E 0093-5049-86

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Feb 3, 2029Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength850MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021842

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-001 Aug 29, 2005 ➤ Sign Up ➤ Sign Up
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-001 Aug 29, 2005 ➤ Sign Up ➤ Sign Up
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-002 Aug 29, 2005 ➤ Sign Up ➤ Sign Up
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-001 Aug 29, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Chubb
Dow
Express Scripts
Covington
Queensland Health
Chinese Patent Office
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.